Floatz logo

(R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-1,4,5,6,7,8-HEXAHYDRO-4AH-PYRAZOLO(3,4-G)ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE

Cushing Syndrome

Corcept TherapeuticsSmall moleculePhase 3Active
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Cushing Syndrome cohort.

Asset / SponsorPhaseRating
Mifepristone
Corcept Therapeutics
Phase 4B
Clofutriben
Sparrow Pharmaceuticals
Phase 2CCC
Metyrapone
Istituto Auxologico Italiano
D
Semaglutide
University of Texas Southwestern Medical Center
N/AD
Solu-Cortef
University Hospital, Bordeaux
N/ANR

Same molecule, other indications

(R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-1,4,5,6,7,8-HEXAHYDRO-4AH-PYRAZOLO(3,4-G)ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE is also rated in:

peritoneal neoplasmDormant
BB
Indicative ·
64 / 100
View asset →
pancreatic ductal adenocarcinomaDormant
BB
Indicative ·
64 / 100
View asset →
ovarian neoplasmDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →